Research
Insurance delays and denials mean kids don't get allergy and asthma medications
The Brief
- A study being presented at the ACAAI 2026 Annual Scientific Meeting examines insurance delays and denials for biologic medicines prescribed to children.
- Biologics are newer medicines prescribed when severe asthma, eczema, hives or food allergy is not controlled.
- The source reports that insurance delays and denials keep some children from receiving these medications.
Why it matters
The findings show that coverage barriers, not only clinical need, can determine whether children with severe allergic and asthma conditions receive recommended treatment.
Who’s affected
- pediatric allergists and asthma specialists
- families of children with severe asthma, eczema, hives or food allergy
- health insurers and policymakers
- ACAAI 2026 Annual Scientific Meeting
- #allergy
- #asthma
- #biologics
- #insurance
- #pediatrics
When a child's severe asthma, eczema, hives or food allergy isn't under control, an allergist may prescribe a newer type of medicine called a biologic. But a new study being presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting…
Timeline
Study on insurance delays and denials for children's biologic medicines reported ahead of presentation at ACAAI 2026 Annual Scientific Meeting
Medical Xpress - latest medical and health news stories
Insurance delays and denials mean kids don't get allergy and asthma medications